CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety of an investigational treatment for
myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine)
stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source -
FDA OOPD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute